Insys Therapeutics has agreed to pay a hefty $225 million to settle criminal and civil investigations into unlawful marketing practices – including kickbacks – to boost sales of an opioid p
Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can be effective in osteoarthritis in higher doses, but lower doses remain ineffective and the dr
As it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi to commercialise Rizmoic (naldemedine) in the key European markets
